Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428654 | 1.00 | PDE7A (0.39) | PDE7APDE7B | |
| SCHEMBL4650091 | 0.90 | HTR2C (0.38) | — | |
| SCHEMBL31567653 | 0.81 | TAS1R3 (0.40) | — | |
| SCHEMBL5027056 | 0.81 | TAS1R3 (0.40) | — | |
| SCHEMBL15577014 | 0.80 | DRD2 (0.49) | — | |
| SCHEMBL16713163 | 0.79 | PDE7A (0.38) | PDE7APDE7B | |
| SCHEMBL28804613 | 0.79 | PDE7A (0.38) | PDE7APDE7B | |
| SCHEMBL22507510 | 0.79 | HTR2C (0.36) | — | |
| SCHEMBL21772217 | 0.79 | PDE7A (0.41) | PDE7APDE7B | |
| SCHEMBL14747966 | 0.79 | HTR2C (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-2185526-B1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2391608-B1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-8334390-B2 | Fungicide N-cycloalkyl-N-bicyclic-carboxamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20100197925-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES | Bater SAS (FR) | 2010-08-05 | — | — | US | disclosed |
| WO-2010086311-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLICMETHYLENE-CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009016218-A2 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-02-05 | — | — | WO | disclosed |
| CN-1045099-A | Ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes | LILLY CO ELI (US) | 1990-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | PDE7A 2723/4885PDE7B 1678/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | PDE7A 825/4885PDE7B 980/4885 |
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | PDE7A 2625/4885PDE7B 1607/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | PDE7A 1939/4885PDE7B 1101/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | PDE7A 2625/4885PDE7B 1607/4885 |
| US-20100197925-A1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES | CBR3, CBR1, CYP3A7 | PDE7A 2606/4885PDE7B 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.